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sides of the horizontal raphe. It is a rare condition, mostly asymptomatic and discovered on routine examination. We describe
a case of both arterial and venous CRM with a macroaneurysm along the arterial CRM that presented with decreased vision
due to prominent lipid exudation at the macula. Treatment with intravitreal bevacizumab resulted in a favourable anatomical as
well as functional outcome. To the best of our knowledge, this is the first report of this unusual presentation of CRM, and its
successful management with intravitreal bevacizumab.
Keywords: Congenital retinal macrovessel, Retinal artery macroaneurysm, Intravitreal bevacizumab
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Saudi Ophthalmological Society, King Saud University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.sjopt.2015.03.001Introduction
The term ‘‘congenital retinal macrovessel’’ (CRM) was
coined by Brown et al. to describe an aberrant retinal vessel,
frequently a vein, crossing the central macula and supplying
or draining both above and below the horizontal raphe.1 The
condition is usually unilateral, and rarely affects visual acuity.1,2
We hereby describe an unusual case of arterial as well as
venous CRM which was associated with reduction in vision.
This was attributed to macular exudation from a macroa-
neurysm along the arterial CRM. The patient was treated
successfully with intravitreal bevacizumab. To the best of our
knowledge, this is the first report of intravitreal bevacizumab
in retinal arteriolar macroaneurysm associated with CRM.
Case report
A 65 year old female presented with complaints of blurred
vision in her left eye since one month before. She had poorvision in her right eye following cataract surgery done 12 years
back. She was a hypertensive well controlled by medication.
On examination, her right eye had no light perception,
due to aphakic bullous keratopathy and secondary glaucoma.
The best corrected visual acuity (BCVA) in her left eye was
20/200. Anterior segment examination including intraocular
pressure was unremarkable apart from the presence of a pos-
terior chamber intraocular lens. Dilated fundus examination
revealed prominent lipid exudation with aberrant vessels at
the centre of the macula (Fig. 1a). Fluorescein angiography
showed an arterial CRM arising from the superior branch of
the central retinal artery (Fig. 1b) and a venous CRM draining
into the inferior branch of the central retinal vein before bifur-
cation (Fig. 1c). A small macroaneurysm was present along
the arterial CRM just temporal to the temporal margin of
the optic disc (Fig. 1c and d). There were prominent retinal
vascular calibre abnormalities of the superotemporal retinal
artery which anastomosed with the numerous branches of
the venous CRM. In addition, there was markedly increasede:
al.com
Figure 1. (a) Colour fundus photograph of the left eye showing macular exudation with aberrant vessels. (b) Fundus fluorescein angiography revealing an
arterial CRM arising from the superior branch of the central retinal artery (red arrow). (c) A venous CRM was also seen draining into the inferior trunk of
the central retinal vein (blue arrow). Just temporal to the temporal margin of the optic disc, filling of a macroaneurysm along the arterial CRM was seen.
(d) Late phase showing leakage from the macroaneurysm, with multiple ill defined leaks in the nasal part of the macula.
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This anomalous capillary network contained multiple pin
point leaks, especially the nasal to the fovea (Fig. 1d). No
capillary nonperfusion areas were noted. Spectral domain
optical coherence tomography (SD-OCT) was performed
and showed intraretinal hard exudates along with retinal
oedema in the nasal part of the macula (Fig. 2a and b).
After being informed about the off-label use of intravitreal
bevacizumab as a treatment option, the patient agreed to
receive an intravitreal injection of bevacizumab (1.25 mg in
0.05 ml) in her left eye. At one month follow up, BCVA
improved to 20/60 with marked decrease in the hard
exudates and macular oedema. A second injection of intravitreal
bevacizumab was administered. At one month following the
second dose, BCVA improved to 20/30 with further reduction
in retinal hard exudates (Fig. 2c). SD-OCT confirmed the
decrease in macular oedema and hard exudates and revealed
normalization of the foveal contour (Fig. 2d). This picture was
maintained till two years follow up with no recurrences.Discussion
A large retinal vessel crossing the horizontal raphe in the
macular area is termed as a CRM. Since the first description
in 1869 by Mauthner,3 fewer than 50 cases have been
reported. A CRM is usually a retinal vein, rarely it could be
an artery or both artery and vein. Our case had both arterial
as well as venous CRM; this has been described rarely in
literature.1,2
CRMs are usually benign and stable and are mostly
detected in asymptomatic patients on routine examination.Occasionally, a CRM can present with decreased vision which
has been attributed to haemorrhage, foveal cyst, the vessel
itself crossing the fovea1,2 and central serous chorioretinopa-
thy.4 Our case presented with a macroaneurysm along the
arterial CRM and prominent macular exudation, with retinal
oedema. Only 2 case reports of arterial CRM with a leaking
macroaneurysm affecting visual acuity were found in litera-
ture.5,6 Koizumi et al. also described a retinal arteriolar
macroaneurysm and CRM, however, both lesions were dis-
tinct and unrelated.7
Macroaneurysms are acquired dilatations of the retinal
arteries that usually occur in elderly hypertensive women. It
has been suggested that the lack of autoregulation in anoma-
lous vessels may contribute to the development of macroa-
neurysms in CRMs.6 Symptomatic macroaneurysms may be
haemorrhagic or exudative.8 While spontaneous involution
of macroaneurysms with functional recovery is known, it has
been suggested that patients with subretinal haemorrhage
or exudative manifestations involving the fovea and visual
acuity deterioration should be treated to avoid irreversible
photoreceptor damage.9 Conventional laser photocoagula-
tion has been the most commonly employed treatment for
symptomatic retinal arterial macroaneurysm, however, in this
patient, the location of the microaneurysm in the region of the
papillomacular bundle was not amenable to this form of ther-
apy. Since the development of retinal artery macroaneurysm
is associated with focal damage to arterial walls, leading to
localized ischaemia and VEGF upregulation, the use of anti-
VEGF agents has been suggested as a treatment modality.
Intravitreal bevacizumab has been shown to hasten resolution
of macular oedema and haemorrhage secondary to retinal
artery macroaneurysm, with improvement in visual acuity.10,11
Figure 2. (a) Colour fundus photograph of the left eye at presentation. (b) Horizontal spectral domain optical coherence tomography (SD-OCT) scan
showing scattered intraretinal hard exudates (also subfoveal) and macular oedema (nasally). (c) Colour fundus photograph of the left eye 2 months after
presentation, following 2 monthly injections of intravitreal bevacizumab. There was considerable reduction in the exudation. (d) Horizontal SD-OCT scan
showing decrease in hard exudates and oedema.
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bevacizumab could have reduced vascular permeability, with
consequent resolution of the lipid exudation and retinal
oedema in our patient. This resulted in considerable
improvement in visual acuity which was maintained till two
years of follow up. While the CRM and macroaneurysm
persisted, there was no recurrent retinal oedema or lipid
exudation. This is the first report of successful treatment of
visual impairment due to a macroaneurysm in an arterial
CRM with intravitreal bevacizumab.
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